US FDA accepts and grants priority review status to Dizal’s sunvozertinib NDA in relapsed or refractory NSCLC patients with EGFR exon20ins: Shanghai Thursday, January 9, 2025, 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback